However, due to time and cost constraints, the surrogate molecular breast cancer classification is still largely based on IHC assessment of biomarkers: estrogen receptor (ER), progesterone receptor (PR), HER-2, and Ki-67, among others (36). This evidence concerns the gene PGR and breast cancer.